New drug cocktail aims to shrink Hard-to-Treat breast tumors
NCT ID NCT07389733
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called HRS-6208 combined with other cancer drugs (HRS-8080, fulvestrant, or letrozole) in 180 adults with advanced breast cancer that cannot be removed by surgery or has spread. The main goals are to find safe doses and see if the combination shrinks tumors. Participants will be monitored for side effects and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-6208 (an experimental drug) combined with other drugs like HRS-8080, fulvestrant, or letrozole
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced breast cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with only 180 participants, so the drugs may not work as hoped or could cause unexpected side effects. Results may not apply to all breast cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER OF ADULTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Dalian Medical University
RECRUITINGDalian, Liaoning, 116031, China
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610044, China